bmm-2022-0113 supplementary table

Aim: Allograft rejection remains a major cause of graft failure in kidney transplantation. Here the authors
report the validation of a non-invasive molecular diagnostic assay, AlloMap Kidney, using peripheral
blood. Methods: The AlloMap Kidney test is a gene expression profile utilizing the RNA-seq platform
to measure immune quiescence in kidney transplant patients. Results/Conclusions: Analytical validation
showed robust performance characteristics with an accuracy correlation coefficient of 0.997 and a
precision coefficient of variation of 0.049 across testing. Clinical validation from the prospective, multicenter
studies of 235 samples (66 rejection and 169 quiescence specimens) demonstrated the sensitivity
of 70% and specificity of 66% for allograft rejection, while the negative predictive value was 95% to
discriminate rejection from quiescence at 10% prevalence of rejection.